InDex Pharmaceuticals Holding AB (publ) interim report January – September 2018
Directed share issue strengthens the cash position ahead of the CONDUCT results
Press releases
InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2019 Annual General Meeting
November 6, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2019 Annual General Meeting, which will be held on Monday May 6, 2019. The responsibility of the Nomination Committee is to present to the 2019 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.
InDex Pharmaceuticals carries out a directed share issue of approximately SEK 37.5 million
October 23, 2018 – The board of directors of InDex Pharmaceuticals Holding AB (publ) (the “Company” or “InDex”) has, with support from the authorization granted by the annual general meeting on May 24, 2018, resolved on a directed share issue of 6,252,842 shares to a small group of investors. The subscription price is SEK 6.02 per share, corresponding to a discount in line with market conditions of 7.7 percent to the 5-day volume weighted average price and 1.3 percent to today’s closing price. InDex will receive proceeds of approximately SEK 37.5 million after transaction related costs for legal services and costs for registration and practical management.
InDex Pharmaceuticals publishes post-hoc analysis of the COLLECT study
October 19, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced the publication of a post-hoc analysis of COLLECT study data. COLLECT was a clinical study of the Toll-like receptor 9 (TLR9) agonist cobitolimod, a first-in-class treatment for patients with moderate to severe ulcerative colitis (UC). The paper, published in the October issue of the peer-reviewed journal Digestive and Liver Disease (DLD), presents the clinical effect of cobitolimod on patient-reported outcomes (PRO) defined endpoints and in different patient subgroups defined by disease activity or anti-TNFα therapy exposure.
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2018
Updated timeline for the top line results from the CONDUCT study
InDex Pharmaceuticals updates timeline for top line results from the CONDUCT study to first half of 2019
August 9, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the drug candidate cobitolimod. Top line results from the study are now expected in the first half of 2019 instead of in the fourth quarter of 2018 as previously communicated.
InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW)
May 31, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the largest congress in the world within gastroenterology. The congress is held in Washington DC, US on June 2-5, 2018.
Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
May 24, 2018 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Thursday, May 24, 2018 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2018
Novel formulation for oral administration of cobitolimod
InDex Pharmaceuticals develops oral formulation of cobitolimod
May 4, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that it has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract. The oral formulation of cobitolimod is a potential follow-on product to the topical formulation, which is currently being investigated in the CONDUCT study – a phase IIb dose optimisation study in moderate to severe active ulcerative colitis.
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2017
April 24, 2018 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2017. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, http://www.indexpharma.com.
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
April 23, 2018 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
InDex Pharmaceuticals announces the agenda for its Capital Markets Day in Stockholm on April 25, 2018
April 12, 2018 – InDex Pharmaceuticals Holding AB (publ) (”InDex”) today announced the agenda for its Capital Markets Day that will take place in Stockholm on Wednesday April 25, 2018, for investors, analysts and media.
InDex Pharmaceuticals gets new patent in Japan
Mars 28, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the Japan Patent Office. The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.
Save the date: InDex Pharmaceuticals to host Capital Markets Day in Stockholm on April 25, 2018
March 26, 2018 – InDex Pharmaceuticals Holding AB (publ) (”InDex”) today announced that the company will host a Capital Markets Day in Stockholm on Wednesday April 25, 2018 for investors, analysts and media.
InDex Pharmaceuticals Holding AB (publ) year end report 2017
Deepened understanding of cobitolimod’s mechanism of action
InDex Pharmaceuticals presents mechanism of action data for cobitolimod at the ECCO congress
February 13, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced that the recently reported new mechanism of action data for the drug candidate cobitolimod has been selected for an oral presentation at the 13th congress of the European Crohn’s and Colitis Organisation (ECCO).
